

Table S1. YM155 concentrations (nM) that reduce the viability of UKF-NB-3 or YM155-adapted UKF-NB-3 sub-lines by 50% (IC₅₀) or 90% (IC₉₀) as indicated by MTT assay after 120h of incubation and doubling times of the cells.

	IC ₅₀	IC ₉₀	Doubling times (h)
UKF-NB-3	0.55 ± 0.06	1.01 ± 0.24	30.8 ± 0.8
UKF-NB-3rYM155 ^{20nM} I	36.2 ± 2.0 (66) ¹	94.8 ± 0.7 (94) ²	41.5 ± 5.2
UKF-NB-3rYM155 ^{20nM} II	23.6 ± 2.2 (43)	39.9 ± 0.9 (40)	39.2 ± 4.8
UKF-NB-3rYM155 ^{20nM} III	31.8 ± 2.3 (58)	49.1 ± 0.2 (49)	32.3 ± 1.1
UKF-NB-3rYM155 ^{20nM} IV	21.0 ± 0.6 (38)	29.8 ± 4.8 (30)	32.2 ± 2.0
UKF-NB-3rYM155 ^{20nM} V	25.1 ± 0.1 (45)	39.5 ± 0.7 (39)	35.3 ± 2.8
UKF-NB-3rYM155 ^{20nM} VI	41.9 ± 5.3 (76)	136 ± 7 (135)	36.3 ± 2.2
UKF-NB-3rYM155 ^{20nM} VII	36.5 ± 5.5 (66)	96.2 ± 23.9 (95)	46.1 ± 2.1
UKF-NB-3rYM155 ^{20nM} VIII	34.5 ± 0.6 (63)	84.7 ± 27.3 (84)	47.0 ± 2.5
UKF-NB-3rYM155 ^{20nM} IX	27.2 ± 0.5 (49)	44.8 ± 2.9 (44)	33.3 ± 0.2
UKF-NB-3rYM155 ^{20nM} X	26.9 ± 0.5 (49)	45.2 ± 4.7 (45)	41.9 ± 2.2

¹ fold resistance (IC₅₀ YM155-adapted sub-line/ IC₅₀ UKF-NB-3)

² fold resistance (IC₉₀ YM155-adapted sub-line/ IC₉₀ UKF-NB-3)

Table S2. Drug concentrations that reduce the viability of UKF-NB-3 or YM155-adapted UKF-NB-3 sub-lines by 50% (IC₅₀) as indicated by MTT assay after 120h of incubation.

	Nutlin-3	Vincristine	Cisplatin	Gemcitabine	Topotecan
	IC ₅₀ (μM)	IC ₅₀ (ng/mL)	IC ₅₀ (ng/mL)	IC ₅₀ (ng/mL)	IC ₅₀ (ng/mL)
UKF-NB-3	1.05 ± 0.25	1.75 ± 0.55	169 ± 29	0.30 ± 0.03	1.29 ± 0.52
UKF-NB-3rYM155 ^{20nM} I	0.57 ± 0.07 (0.5) ¹	45.5 ± 11.1 (26)	157 ± 54 (0.9)	0.64 ± 0.02 (2.1)	1.37 ± 0.53 (1.1)
UKF-NB-3rYM155 ^{20nM} II	1.31 ± 0.03 (1.2)	27.0 ± 12.6 (15)	183 ± 51 (1.1)	0.50 ± 0.04 (1.7)	1.25 ± 0.53 (1.0)
UKF-NB-3rYM155 ^{20nM} III	1.27 ± 0.01 (1.2)	10.8 ± 6.4 (6.2)	122 ± 24 (0.7)	0.62 ± 0.01 (2.1)	1.06 ± 0.24 (0.8)
UKF-NB-3rYM155 ^{20nM} IV	0.47 ± 0.03 (0.4)	18.5 ± 8.4 (11)	159 ± 38 (0.9)	0.23 ± 0.04 (0.8)	1.56 ± 0.65 (1.2)
UKF-NB-3rYM155 ^{20nM} V	0.99 ± 0.13 (0.9)	8.90 ± 7.39 (5.1)	156 ± 84 (0.9)	0.12 ± 0.04 (0.4)	0.91 ± 0.41 (0.7)
UKF-NB-3rYM155 ^{20nM} VI	0.64 ± 0.01 (0.6)	714 ± 456 (408)	132 ± 39 (0.8)	0.64 ± 0.01 (2.1)	1.55 ± 0.72 (1.2)
UKF-NB-3rYM155 ^{20nM} VII	1.27 ± 0.04 (1.2)	28.8 ± 10.2 (16)	134 ± 6 (0.8)	0.19 ± 0.01 (0.6)	1.44 ± 0.84 (1.1)
UKF-NB-3rYM155 ^{20nM} VIII	0.70 ± 0.01 (0.7)	39.5 ± 15.4 (23)	190 ± 56 (1.1)	0.65 ± 0.01 (2.2)	1.26 ± 0.50 (1.0)
UKF-NB-3rYM155 ^{20nM} IX	0.33 ± 0.01 (0.3)	5.63 ± 1.94 (3.2)	178 ± 41 (1.1)	0.18 ± 0.01 (0.6)	1.59 ± 0.74 (1.2)
UKF-NB-3rYM155 ^{20nM} X	0.64 ± 0.15 (0.6)	26.0 ± 6.2 (15)	144 ± 44 (0.9)	0.54 ± 0.01 (1.8)	1.21 ± 0.40 (0.9)

¹ fold resistance (IC₅₀ YM155-adapted sub-line/ IC₅₀ UKF-NB-3)

Figure S1




Figure S1




Figure S1




Figure S1. Representative photos of the project cell lines indicating cell morphology after different periods of cultivation and at different magnifications.

Figure S2




Figure S2. p53 levels in UKF-NB-3 and its YM155-adapted sublines.

Figure S2. Representative Western blots indicating cellular levels of p53 in UKF-NB-3 and YM155-adapted UKF-NB-3 sub-lines. Densitometric analysis was performed with QuantiOne (BioRad). p53 levels were normalised to β -actin expression and values relative to control cells are displayed.

Figure S2





Figure S2





Figure S2





Figure S2





Figure S3




Figure S3. Representative Western blots indicating cellular levels of survivin in UKF-NB-3 and YM155-adapted UKF-NB-3 sub-lines. Densitometric analysis was performed with Image Studio Ver. 5.2 software (LICOR). Survivin levels were normalised to β -actin expression and values relative to control cells are displayed.

Figure S3





Figure S3





Figure S3





Figure S3





Figure S4
survivin







Figure S4

GAPDH





Figure S4
survivin





Figure S4
GAPDH






Figure S4
survivin





Figure S4
GAPDH





Figure S4 survivin





Figure S4 GAPDH




Figure S4. Representative Western blots indicating cellular levels of survivin in UKF-NB-3 and its YM155-adapted UKF-NB-3 sub-lines 24h after transfection with non-targeting siRNA or siRNA directed against BIRC5/ survivin. Densitometric analysis was performed with QuantiOne (BioRad). Survivin levels were normalised to β -actin expression and values relative to control cells are displayed.

Figure S5
ABCB1





Figure S5 SLC35F2





Figure S5 SLC35F2





Figure S5
 β -actin




Figure S5
 β -actin




Figure S5. Representative Western blots indicating cellular levels of ABCB1 and SLC35F2 in UKF-NB-3 and YM155-adapted UKF-NB-3 sub-lines. Densitometric analysis was performed with QuantiOne (BioRad). ABCB1 and SLC35F2 levels were normalised to β -actin expression and values relative to control cells are displayed.